TY - JOUR T1 - Diagnosis, Treatment Response, and Prognosis: The Role of <sup>18</sup>F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with <sup>123</sup>I-mIBG Scan: The First Prospective Study JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 367 LP - 374 DO - 10.2967/jnumed.119.232553 VL - 61 IS - 3 AU - Arnoldo Piccardo AU - Giovanni Morana AU - Matteo Puntoni AU - Sara Campora AU - Stefania Sorrentino AU - Pietro Zucchetta AU - Martina Ugolini AU - Massimo Conte AU - Angelina Cistaro AU - Giulia Ferrarazzo AU - Marco Pescetto AU - Marco Lattuada AU - Gianluca Bottoni AU - Alberto Garaventa AU - Luca Giovanella AU - Egesta Lopci Y1 - 2020/03/01 UR - http://jnm.snmjournals.org/content/61/3/367.abstract N2 - Our purpose was to evaluate the diagnostic role of 18F-3,4-dihydroxyphenylalanine (DOPA) PET/CT at the time of staging in children with neuroblastoma and to investigate its ability to assess treatment response. We also investigated the prognostic value of 18F-DOPA PET/CT at the same time points. Methods: We enrolled children with neuroblastoma at onset. Before and after induction chemotherapy, all patients underwent 18F-DOPA PET/CT and 123I-metaiodobenzylguanidine (MIBG) scanning plus SPECT/CT. 18F-DOPA PET/CT results were compared with those of 123I-MIBG whole-body scanning (WBS). For each modality, patient-based analysis and lesion-based analysis were performed and sensitivity was calculated. We applied scoring systems to 123I-MIBG scanning and 18F-DOPA PET/CT (i.e.,123I-MIBG WBS score and whole-body metabolic burden [WBMB], respectively) and evaluated the association between these parameters, the principal neuroblastoma risk factors, and outcome. Results: We enrolled 16 high-risk and 2 intermediate-risk neuroblastoma patients. On patient-based analysis, sensitivity in detecting primary tumors, soft-tissue metastases, and bone or bone-marrow metastases was 83%, 50%, and 92%, respectively, for 123I-MIBG WBS versus 94%, 92%, and 100%, respectively, for 18F-DOPA PET/CT. On lesion-based analysis, the sensitivity of 18F-DOPA PET/CT in detecting soft-tissue and bone or bone-marrow metastases was 86% and 99%, respectively—significantly higher than that of 123I-MIBG WBS, at 41% and 93%, respectively. After therapy, on patient-based analysis, the sensitivity in detecting primary tumors, soft-tissue metastases, and bone or bone-marrow metastases was 72%, 33%, and 38%, respectively, for 123I-MIBG WBS versus 83%, 75% and 54%, respectively, for 18F-DOPA PET/CT. On lesion-based analysis, the sensitivity of 18F-DOPA PET/CT in detecting soft-tissue and bone or bone-marrow metastases was 77% and 86%, respectively—significantly higher than that of 123I-MIBG WBS, at 28% and 69%, respectively. During follow-up, 8 cases of disease progression and 5 deaths occurred. On multivariate analysis, only posttherapeutic 18F-DOPA WBMB (&gt;7.5) was associated with progression-free survival. Conclusion: 18F-DOPA PET/CT is more sensitive than 123I-MIBG WBS in staging neuroblastoma patients and evaluating disease persistence after chemotherapy. In a time-to-event analysis, posttherapeutic 18F-DOPA WBMB remained the only risk factor associated with disease progression. ER -